Literature DB >> 22277677

Inter-individual variability of in vivo CYP2D6 activity in different genotypes.

Koji Chiba1, Motohiro Kato, Takashi Ito, Toshio Suwa, Yuichi Sugiyama.   

Abstract

Cytochrome P450 2D6 (CYP2D6), which has a large number of genetic polymorphisms, is involved in the metabolism of a wide range of substrates. Dextromethorphan (DM) is a well-known probe drug for CYP2D6 and metabolic ratio (MR) is often used to measure the enzyme activity in vivo. Using the literature values of DM MR, we estimated the inter-individual variability of CYP2D6 hepatic intrinsic clearance (CL(int,h,2D6)) in each genotype by Monte Carlo simulation and found that the homozygote of CYP2D6*1 and the heterozygote of CYP2D6*1 and null alleles had a coefficient of variation (CV) of 43% and 56%, respectively. The variability of homozygotes of CYP2D6*2 and CYP2D6*10 was 63% and 66%, while that of the heterozygotes of CYP2D6*2 and null alleles and CYP2D6*10 and null alleles was 125% and 109%, respectively. Based on the variability and reported frequency of the CYP2D6 genotype in Asians and Caucasians, the inter-individual variability of CL(int,h,2D6) of extensive metabolizers was estimated at 60-70%, which provided comparable variability of AUC with the literature values of DM, tolterodine, risperidone and atomoxetine. It is suggested that the produced inter-individual variability of CL(int,h,2D6) in each genotype is useful for estimating AUC variability of the CYP2D6 substrates in the regional population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22277677     DOI: 10.2133/dmpk.dmpk-11-rg-078

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  4 in total

1.  Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability.

Authors:  Caroline L Ring; Robert G Pearce; R Woodrow Setzer; Barbara A Wetmore; John F Wambaugh
Journal:  Environ Int       Date:  2017-06-16       Impact factor: 9.621

2.  Rapid onset of syndrome of inappropriate antidiuretic hormone secretion induced by duloxetine in an elderly type 2 diabetic patient with painful diabetic neuropathy.

Authors:  Shinji Kamei; Hideaki Kaneto; Akihito Tanabe; Shintaro Irie; Yurie Hirata; Masashi Shimoda; Kenji Kohara; Tomoatsu Mune; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2014-12-29       Impact factor: 4.232

3.  Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.

Authors:  Toshimichi Nakamura; Kota Toshimoto; Wooin Lee; Chiyo K Imamura; Yusuke Tanigawara; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-06-19

4.  Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.

Authors:  Yaowei Zhu; Yan Xu; Yanli Zhuang; Alexa Piantone; Cathye Shu; Dion Chen; Honghui Zhou; Zhenhua Xu; Amarnath Sharma
Journal:  Clin Transl Sci       Date:  2020-05-28       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.